These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32808083)

  • 21. Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation.
    Sun Y; Liu X; Xu Y
    J Interv Card Electrophysiol; 2020 Sep; 58(3):381-399. PubMed ID: 32458179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy.
    Zeljkovic I; Brusich S; Scherr D; Velagic V; Traykov V; Pernat A; Anic A; Szavits Nossan J; Jan M; Bakotic Z; Pezo Nikolic B; Radeljic V; Bojko A; Benko I; Manola S; Pavlovic N
    Clin Cardiol; 2021 Aug; 44(8):1177-1182. PubMed ID: 34196416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation.
    Harada M; Motoike Y; Nomura Y; Nishimura A; Koshikawa M; Murayama K; Ohno Y; Watanabe E; Izawa H; Ozaki Y
    J Arrhythm; 2020 Jun; 36(3):417-424. PubMed ID: 32528566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
    Snipelisky D; Ray JC; Ung R; Duart M; Kauffman C; Kusumoto F
    J Interv Card Electrophysiol; 2014 Dec; 41(3):231-6. PubMed ID: 25380703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
    Trujillo TC; Dobesh PP; Crossley GH; Finks SW
    Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis.
    Lu D; Zhang Q; Liu Q; Wang K; Wang S; Shan Q
    J Interv Card Electrophysiol; 2015 Nov; 44(2):105-11. PubMed ID: 26342485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
    Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
    Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
    Vlachos K; Efremidis M; Bazoukis G; Letsas KP; Saplaouras A; Georgopoulos S; Karamichalakis N; Rokiza A; Sakellaropoulou A; Kolokathis AM; Efremidis T; Asvestas D; Sideris A
    Clin Cardiol; 2017 Oct; 40(10):847-852. PubMed ID: 28561951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel protocol for initial heparin administration during catheter ablation for atrial fibrillation in patients taking direct oral anticoagulants.
    Kishima H; Mine T; Fukuhara E; Ashida K; Ishihara M; Masuyama T
    Heart Vessels; 2019 May; 34(5):832-841. PubMed ID: 30390125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
    Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
    Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.
    Bin Abdulhak AA; Kennedy KF; Gupta S; Giocondo M; Ramza B; Wimmer AP
    J Interv Card Electrophysiol; 2015 Nov; 44(2):91-6. PubMed ID: 26292959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
    Hansen PS; Sanchez R; Walfridsson H
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review.
    Vrachatis DA; Giannopoulos G; Kossyvakis C; Panagopoulou V; Vavuranakis M; Papaioannou TG; Pagoni S; Pyrgakis VN; Cleman MW; Deftereos SG
    Curr Pharm Des; 2017; 23(9):1334-1345. PubMed ID: 27917710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Bin Abdulhak AA; Khan AR; Tleyjeh IM; Spertus JA; Sanders SU; Steigerwalt KE; Garbati MA; Bahmaid RA; Wimmer AP
    Europace; 2013 Oct; 15(10):1412-20. PubMed ID: 23954918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.